

31 January 2022

Attention:

Ms Michaels
The Society of Hospital Pharmacists of Australia (SHPA)

RE. NOTIFICATION OF OUT OF STOCK PERIOD FOR OPDIVO (NIVOLUMAB) 100MG/10ML AND 40MG/4ML VIALS CONCENTRATE SOLUTION FOR INTRAVENOUS INFUSION

Dear Ms Michaels,

On behalf of Bristol-Myers Squibb Australia Pty Ltd (BMS) I am writing to inform you that:

- From the end of February (anticipated week commencing 28 February 2022), the Opdivo (Nivolumab) 40mg /4mL vial concentrate solution for intravenous infusion will be out of stock in Australia and not available. We anticipate that this situation will last 3-4 weeks.
- Assuming an increased demand, we anticipate from early March (week commencing 7 March) Opdivo (Nivolumab) 100mg /10mL vial concentrate solution for intravenous infusion will also be out of stock in Australia and not available. We anticipate that this situation will last 2-3 weeks.

These stock shortages are related to manufacturing, logistics and supply constraints. We are working to resolve this matter as soon as possible. BMS knows the importance of a steady and reliable supply of critical medicines for patients and remains committed to delivering this medicine to patients who need it.

BMS have notified the Therapeutics Goods Administration (TGA) of this supply shortage. If you could please disseminate this information to the SHPA members, it would be greatly appreciated.

Product Details

BMS Code	BMS Product	Anticipated	Resolved supply
1394080	OPDIVO SINJ 40MG (1VLX4ML) AU	Week commencing 28 February 2022	Week commencing 21 March 2022
1394152	OPDIVO SINJ 100MG (1VLX10ML) AU	Week commencing 7 March 2022	Week commencing 21 March 2022

If you have any questions relating to the shortage, please contact the BMS Medical Information Department at 1800 067 567 or via email at: medinfo.australia@bms.com.

Yours sincerely,

Kate Church
Bristol-Myers Squibb Australia